ATHERSYS INC (ATHX) Stock Price, Forecast & Analysis
NASDAQ:ATHX • US04744L2051
ATHX Key Statistics, Chart & Performance
The current stock price of ATHX is 0.1018 USD. In the past month the price decreased by -67.28%. In the past year, price decreased by -94.94%.
ATHX Technical Analysis
ATHX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ATHX. ATHX may be in some trouble as it scores bad on both profitability and health.
ATHX Financial Highlights
Over the last trailing twelve months ATHX reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 64.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -452.29% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATHX Forecast & Estimates
7 analysts have analysed ATHX and the average price target is 5.61 USD. This implies a price increase of 5410.81% is expected in the next year compared to the current price of 0.1018.
For the next year, analysts expect an EPS growth of 83.47% and a revenue growth -100% for ATHX
ATHX Ownership
ATHX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 402.079B | ||
| AMGN | AMGEN INC | 16.38 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.92 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ATHX
Company Profile
Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. The company is headquartered in Cleveland, Ohio and currently employs 24 full-time employees. The company went IPO on 2007-04-23. The firm is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
Company Info
ATHERSYS INC
3201 Carnegie Ave
CLEVELAND OHIO 44115 US
CEO: William Lehmann Jr.
Employees: 24
Phone: 12164319900.0
ATHERSYS INC / ATHX FAQ
What does ATHERSYS INC do?
Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. The company is headquartered in Cleveland, Ohio and currently employs 24 full-time employees. The company went IPO on 2007-04-23. The firm is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
Can you provide the latest stock price for ATHERSYS INC?
The current stock price of ATHX is 0.1018 USD. The price increased by 3.77% in the last trading session.
Does ATHERSYS INC pay dividends?
ATHX does not pay a dividend.
What is the ChartMill rating of ATHERSYS INC stock?
ATHX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ATHX stock?
ATHX stock is listed on the Nasdaq exchange.
What is the market capitalization of ATHX stock?
ATHERSYS INC (ATHX) has a market capitalization of 2.29M USD. This makes ATHX a Nano Cap stock.
Who owns ATHERSYS INC?
You can find the ownership structure of ATHERSYS INC (ATHX) on the Ownership tab.